tetano
Editor, Senior Moderator
PLoS One
. 2021 Jun 4;16(6):e0252799.
doi: 10.1371/journal.pone.0252799. eCollection 2021.
Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients
Tue W Kragstrup[SUP] 1 2 [/SUP], Helene Søgaard Singh[SUP] 1 [/SUP], Ida Grundberg[SUP] 3 [/SUP], Ane Langkilde-Lauesen Nielsen[SUP] 1 4 [/SUP], Felice Rivellese[SUP] 5 [/SUP], Arnav Mehta[SUP] 6 7 [/SUP], Marcia B Goldberg[SUP] 8 9 [/SUP], Michael R Filbin[SUP] 10 [/SUP], Per Qvist[SUP] 1 11 12 [/SUP], Bo Martin Bibby[SUP] 13 [/SUP]
Affiliations
Abstract
Aims: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the infection termed coronavirus disease of 2019 (COVID-19). Here, we investigate associations between plasma ACE2 and outcome of COVID-19.
Methods and results: This analysis used data from a large longitudinal study of 306 COVID-19 positive patients and 78 COVID-19 negative patients (MGH Emergency Department COVID-19 Cohort). Comprehensive clinical data were collected on this cohort, including 28-day outcomes. The samples were run on the Olink® Explore 1536 platform which includes measurement of the ACE2 protein. High admission plasma ACE2 in COVID-19 patients was associated with increased maximal illness severity within 28 days with OR = 1.8, 95%-CI: 1.4-2.3 (P < 0.0001). Plasma ACE2 was significantly higher in COVID-19 patients with hypertension compared with patients without hypertension (P = 0.0045). Circulating ACE2 was also significantly higher in COVID-19 patients with pre-existing heart conditions and kidney disease compared with patients without these pre-existing conditions (P = 0.0363 and P = 0.0303, respectively).
Conclusion: This study suggests that measuring plasma ACE2 is potentially valuable in predicting COVID-19 outcomes. Further, ACE2 could be a link between COVID-19 illness severity and its established risk factors hypertension, pre-existing heart disease and pre-existing kidney disease.
. 2021 Jun 4;16(6):e0252799.
doi: 10.1371/journal.pone.0252799. eCollection 2021.
Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients
Tue W Kragstrup[SUP] 1 2 [/SUP], Helene Søgaard Singh[SUP] 1 [/SUP], Ida Grundberg[SUP] 3 [/SUP], Ane Langkilde-Lauesen Nielsen[SUP] 1 4 [/SUP], Felice Rivellese[SUP] 5 [/SUP], Arnav Mehta[SUP] 6 7 [/SUP], Marcia B Goldberg[SUP] 8 9 [/SUP], Michael R Filbin[SUP] 10 [/SUP], Per Qvist[SUP] 1 11 12 [/SUP], Bo Martin Bibby[SUP] 13 [/SUP]
Affiliations
- PMID: 34086837
- DOI: 10.1371/journal.pone.0252799
Abstract
Aims: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the infection termed coronavirus disease of 2019 (COVID-19). Here, we investigate associations between plasma ACE2 and outcome of COVID-19.
Methods and results: This analysis used data from a large longitudinal study of 306 COVID-19 positive patients and 78 COVID-19 negative patients (MGH Emergency Department COVID-19 Cohort). Comprehensive clinical data were collected on this cohort, including 28-day outcomes. The samples were run on the Olink® Explore 1536 platform which includes measurement of the ACE2 protein. High admission plasma ACE2 in COVID-19 patients was associated with increased maximal illness severity within 28 days with OR = 1.8, 95%-CI: 1.4-2.3 (P < 0.0001). Plasma ACE2 was significantly higher in COVID-19 patients with hypertension compared with patients without hypertension (P = 0.0045). Circulating ACE2 was also significantly higher in COVID-19 patients with pre-existing heart conditions and kidney disease compared with patients without these pre-existing conditions (P = 0.0363 and P = 0.0303, respectively).
Conclusion: This study suggests that measuring plasma ACE2 is potentially valuable in predicting COVID-19 outcomes. Further, ACE2 could be a link between COVID-19 illness severity and its established risk factors hypertension, pre-existing heart disease and pre-existing kidney disease.